NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

抗驚厥藥市場規模調查:按藥物類型,應用2025-COVID-19的累積影響進行的全球預測

Anticonvulsants Market Research Report by Drug types, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

出版商 360iResearch LLP 商品編碼 995368
出版日期 內容資訊 英文 194 Pages
商品交期: 最快1-2個工作天內
價格
抗驚厥藥市場規模調查:按藥物類型,應用2025-COVID-19的累積影響進行的全球預測 Anticonvulsants Market Research Report by Drug types, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19
出版日期: 2021年06月01日內容資訊: 英文 194 Pages
簡介

預計全球抗驚厥藥物市場將從2020年的9,452.37百萬美元增長到2025年底的13,648.43百萬美元。

預計COVID-19將在預測期內對行業增長產生長期影響,因為這是無與倫比的全球公共衛生突發事件,幾乎影響了每個行業。我們正在進行的研究擴大了研究框架,以確保它包括潛在的COVID-19問題和潛在的未來路徑。該調查提供了對COVID-19的見解,並考慮了消費者行為和需求,購買模式,供應鏈改路,當前市場勢力動態以及政府的主要干預措施的變化。更新後的調查提供了見解,分析,估計和預測,其中考慮了COVID-19對市場的影響。

本報告調查了抗驚厥藥市場,分析了市場概況,市場增長和障礙,市場規模趨勢以及按類型,應用和區域以及累計COVID-19的預測,提供了有關影響,競爭條件,關鍵因素的全面信息。公司簡介,市場機會等。

目錄

第1章簡介

  • 調查目的
  • 市場細分和覆蓋範圍
  • 調查目標年度
  • 貨幣和價格
  • 語言
  • 限制
  • 利益相關者

第2章調查方法

  • 調查過程
    • 定義:調查目的
    • 決策:調查設計
    • 準備:測量設備
    • 集合:數據源
    • 分析:數據解釋
    • 公式:數據驗證
    • 已發佈:調查報告
    • 重複:報告更新
  • 進行調查
    • 開始:調查過程
    • 計劃:創建調查計劃
    • 執行:進行調查
    • 驗證:發現和分析
    • 出版物:調查報告
  • 調查結果

第3章執行摘要

  • 市場前景
  • 按藥物類型劃分的展望
  • 按應用程序劃分的展望
  • 區域展望
  • 競爭對手展望

第4章市場概述

  • COVID-19的累積效果

第5章市場洞察

  • 市場動態
    • 促進因素
    • 抑制因素
    • 市場機會
    • 挑戰
  • 波特五力分析
    • 新進入者的威脅
    • 替代威脅
    • 客戶的議價能力
    • 供應商的談判能力
    • 行業競爭

第6章全球抗驚厥藥市場:按藥物類型

  • AMPA
  • 巴比妥酸鹽
  • 苯二氮卓
  • 氨基甲酸酯類抗驚厥藥
  • 碳酸酐□抑製劑
  • Dibenzazepine
  • 三秦

第7章全球抗驚厥藥市場:按用途

  • 焦慮
  • 躁鬱症
  • 邊緣人格障礙
  • 癲癇病
  • 纖維肌痛
  • 偏頭痛
  • 神經性疼痛

第8章美洲抗驚厥藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太抗驚厥藥市場

  • 澳大利亞
  • 中國
  • 印度
  • 印度尼西亞
  • 日本
  • 馬來西亞
  • 菲律賓
  • 韓國
  • 泰國

第10章歐洲,中東和非洲的抗驚厥市場

  • 法國
  • 德國
  • 意大利
  • 荷蘭
  • 卡塔爾
  • 俄羅斯
  • 沙特阿拉伯
  • 南非
  • 西班牙
  • 阿拉伯聯合酋長國
  • 英國

第11章競爭情況

  • FPNV定位矩陣
    • 象限
    • 經營策略
    • 產品滿意度
  • 市場排名分析
  • 市場份額分析
  • 競爭性SWOT分析
  • 競爭情況
    • 併購
    • 協議,合作和夥伴關係
    • 推出和增強新產品
    • 投融資
    • 獎賞,表彰,擴張

第12章企業可用性簡介

  • Abbott Laboratories
  • Astrazeneca PLC
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Cadila Pharmaceuticals Limited
  • Cipla, Inc.
  • Eisai Co., Ltd. by Royalty Pharma
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • GW Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lundbeck A/S
  • Mankind Pharma Ltd
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Pharmaceutical
  • Pfizer Inc.
  • Sanofi S.A
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Limited

第13章附錄

  • 討論指南
  • 許可證和價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MRR-ED54C46E805C

The Global Anticonvulsants Market size was estimated at USD 9.45 Billion in 2020 and expected to reach USD 10.22 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 8.51% to reach USD 15.43 Billion by 2026.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Anticonvulsants to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug types, the Anticonvulsants Market was studied across AMPA, Barbiturate, Benzodiazepine, Carbamate Anticonvulsants, Carbonic Anhydrase Inhibitor, Dibenzazepine, and Triazine.

Based on Application , the Anticonvulsants Market was studied across Anxiety, Bipolar Disorder, Borderline Personality Disorder., Epilepsy, Fibromyalgia, Migraine, and Neuropathic Pain.

Based on Geography, the Anticonvulsants Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anticonvulsants Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Anticonvulsants Market, including Abbott Laboratories, Astrazeneca PLC, Bausch Health Companies Inc., Biocon Limited, Cadila Pharmaceuticals Limited, Cipla, Inc., Eisai Co., Ltd. by Royalty Pharma, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., GW Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lundbeck A/S, Mankind Pharma Ltd, Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical, Pfizer Inc., Sanofi S.A, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Wockhardt Limited.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Anticonvulsants Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anticonvulsants Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anticonvulsants Market?
  • 4. What is the competitive strategic window for opportunities in the Global Anticonvulsants Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Anticonvulsants Market?
  • 6. What is the market share of the leading vendors in the Global Anticonvulsants Market?
  • 7. What modes and strategic moves are considered suitable for entering the Global Anticonvulsants Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug types Outlook
  • 3.4. Application Outlook
  • 3.5. Geography Outlook
  • 3.6. Competitor Outlook

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalences of epilepsy
      • 5.1.1.2. Rising investment and support from the government
    • 5.1.2. Restraints
      • 5.1.2.1. Patent expiration of the second-generation drugs
      • 5.1.2.2. Availability of substitutes options for pain management
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
    • 5.1.4. Challenges
      • 5.1.4.1. Steep rise in medicine supply shortage for patients
  • 5.2. Cumulative Impact of COVID-19
  • 5.3. Porters Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry

6. Anticonvulsants Market, by Drug types

  • 6.1. Introduction
  • 6.2. AMPA
  • 6.3. Barbiturate
  • 6.4. Benzodiazepine
  • 6.5. Carbamate Anticonvulsants
  • 6.6. Carbonic Anhydrase Inhibitor
  • 6.7. Dibenzazepine
  • 6.8. Triazine

7. Anticonvulsants Market, by Application

  • 7.1. Introduction
  • 7.2. Anxiety
  • 7.3. Bipolar Disorder
  • 7.4. Borderline Personality Disorder.
  • 7.5. Epilepsy
  • 7.6. Fibromyalgia
  • 7.7. Migraine
  • 7.8. Neuropathic Pain

8. Americas Anticonvulsants Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States
    • 8.6.1. California
    • 8.6.2. Florida
    • 8.6.3. Illinois
    • 8.6.4. New York
    • 8.6.5. Ohio
    • 8.6.6. Pennsylvania
    • 8.6.7. Texas

9. Asia-Pacific Anticonvulsants Market

  • 9.1. Introduction
  • 9.2. China
  • 9.3. India
  • 9.4. Indonesia
  • 9.5. Japan
  • 9.6. Malaysia
  • 9.7. Philippines
  • 9.8. South Korea
  • 9.9. Thailand

10. Europe, Middle East & Africa Anticonvulsants Market

  • 10.1. Introduction
  • 10.2. France
  • 10.3. Germany
  • 10.4. Italy
  • 10.5. Netherlands
  • 10.6. Qatar
  • 10.7. Russia
  • 10.8. Saudi Arabia
  • 10.9. South Africa
  • 10.10. Spain
  • 10.11. United Arab Emirates
  • 10.12. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
    • 11.1.1. Quadrants
    • 11.1.2. Business Strategy
    • 11.1.3. Product Satisfaction
  • 11.2. Market Ranking Analysis
  • 11.3. Market Share Analysis, By Quadrant
  • 11.4. Market Share Analysis, By Company
  • 11.5. Competitive Scenario
    • 11.5.1. Merger & Acquisition
    • 11.5.2. Agreement, Collaboration, & Partnership
    • 11.5.3. New Product Launch & Enhancement
    • 11.5.4. Investment & Funding
    • 11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles

  • 12.1. Abbott Laboratories
  • 12.2. Astrazeneca PLC
  • 12.3. Bausch Health Companies Inc.
  • 12.4. Biocon Limited
  • 12.5. Cadila Pharmaceuticals Limited
  • 12.6. Cipla, Inc.
  • 12.7. Eisai Co., Ltd. by Royalty Pharma
  • 12.8. GlaxoSmithKline PLC
  • 12.9. Glenmark Pharmaceuticals Ltd.
  • 12.10. GW Pharmaceuticals PLC
  • 12.11. Johnson & Johnson Services, Inc.
  • 12.12. Lundbeck A/S
  • 12.13. Mankind Pharma Ltd
  • 12.14. Merck KGaA
  • 12.15. Novartis AG
  • 12.16. Novo Nordisk A/S
  • 12.17. Otsuka Pharmaceutical
  • 12.18. Pfizer Inc.
  • 12.19. Sanofi S.A
  • 12.20. Sunovion Pharmaceuticals Inc.
  • 12.21. Takeda Pharmaceutical Company Limited
  • 12.22. Teva Pharmaceutical Industries Ltd.
  • 12.23. Wockhardt Limited

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing
  • 13.3. Contact Details

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTICONVULSANTS MARKET SIZE, 2020 VS 2026 (USD BILLION)
  • FIGURE 2. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2020 (USD BILLION)
  • FIGURE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2020 (USD BILLION)
  • FIGURE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2020 (USD BILLION)
  • FIGURE 5. GLOBAL ANTICONVULSANTS MARKET: MARKET DYNAMICS
  • FIGURE 6. GLOBAL ANTICONVULSANTS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2020 VS 2026 (%)
  • FIGURE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2020 VS 2026 (USD BILLION)
  • FIGURE 9. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2026
  • FIGURE 10. GLOBAL ANTICONVULSANTS MARKET SIZE, BY AMPA, 2018-2026 (USD BILLION)
  • FIGURE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY AMPA, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, 2018-2026 (USD BILLION)
  • FIGURE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 14. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, 2018-2026 (USD BILLION)
  • FIGURE 15. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 16. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, 2018-2026 (USD BILLION)
  • FIGURE 17. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 18. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, 2018-2026 (USD BILLION)
  • FIGURE 19. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 20. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, 2018-2026 (USD BILLION)
  • FIGURE 21. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 22. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, 2018-2026 (USD BILLION)
  • FIGURE 23. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 24. GLOBAL ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2020 VS 2026 (%)
  • FIGURE 25. GLOBAL ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2020 VS 2026 (USD BILLION)
  • FIGURE 26. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2026
  • FIGURE 27. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ANXIETY, 2018-2026 (USD BILLION)
  • FIGURE 28. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 29. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, 2018-2026 (USD BILLION)
  • FIGURE 30. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 31. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER., 2018-2026 (USD BILLION)
  • FIGURE 32. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER., BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 33. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, 2018-2026 (USD BILLION)
  • FIGURE 34. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 35. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, 2018-2026 (USD BILLION)
  • FIGURE 36. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 37. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, 2018-2026 (USD BILLION)
  • FIGURE 38. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 39. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2026 (USD BILLION)
  • FIGURE 40. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 41. AMERICAS ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 42. AMERICAS ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 44. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 45. BRAZIL ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 46. CANADA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 47. MEXICO ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 48. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 49. CALIFORNIA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 50. FLORIDA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 51. ILLINOIS ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 52. NEW YORK ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 53. OHIO ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 54. PENNSYLVANIA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 55. TEXAS ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 56. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 57. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 58. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 59. CHINA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 60. INDIA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 61. INDONESIA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 62. JAPAN ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 63. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 64. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 65. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 66. THAILAND ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 67. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
  • FIGURE 68. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD BILLION)
  • FIGURE 69. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2026
  • FIGURE 70. FRANCE ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 71. GERMANY ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 72. ITALY ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 73. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 74. QATAR ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 75. RUSSIA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 76. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 77. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 78. SPAIN ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 79. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 80. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD BILLION)
  • FIGURE 81. GLOBAL ANTICONVULSANTS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 82. GLOBAL ANTICONVULSANTS MARKET: SHARE, BY QUADRANT, 2020
  • FIGURE 83. GLOBAL ANTICONVULSANTS MARKET: SHARE, BY COMPANY, 2020
  • FIGURE 84. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTICONVULSANTS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. GLOBAL ANTICONVULSANTS MARKET: MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
  • TABLE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY AMPA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 10. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 14. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER., BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 15. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 16. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 17. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 18. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 19. AMERICAS ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 20. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 21. AMERICAS ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 22. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 23. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 24. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 25. BRAZIL ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 26. CANADA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 27. CANADA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 28. MEXICO ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 29. MEXICO ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 30. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 31. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 32. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 33. CALIFORNIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 34. CALIFORNIA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 35. FLORIDA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 36. FLORIDA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 37. ILLINOIS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 38. ILLINOIS ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 39. NEW YORK ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 40. NEW YORK ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 41. OHIO ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 42. OHIO ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 43. PENNSYLVANIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 44. PENNSYLVANIA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 45. TEXAS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 46. TEXAS ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 47. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 48. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 49. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 50. CHINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 51. CHINA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 52. INDIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 53. INDIA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 54. INDONESIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 55. INDONESIA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 56. JAPAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 57. JAPAN ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 58. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 59. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 60. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 61. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 62. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 63. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 64. THAILAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 65. THAILAND ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 69. FRANCE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 70. FRANCE ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 71. GERMANY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 72. GERMANY ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 73. ITALY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 74. ITALY ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 75. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 76. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 77. QATAR ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 78. QATAR ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 79. RUSSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 80. RUSSIA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 81. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 82. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 83. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 84. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 85. SPAIN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 86. SPAIN ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 87. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 88. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 89. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 90. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY APPLICATION , 2018-2026 (USD/EUR/GBP/JPY/AUD BILLION)
  • TABLE 91. GLOBAL ANTICONVULSANTS MARKET: SCORES
  • TABLE 92. GLOBAL ANTICONVULSANTS MARKET: BUSINESS STRATEGY
  • TABLE 93. GLOBAL ANTICONVULSANTS MARKET: PRODUCT SATISFACTION
  • TABLE 94. GLOBAL ANTICONVULSANTS MARKET: RANKING
  • TABLE 95. GLOBAL ANTICONVULSANTS MARKET: SHARE, BY QUADRANT, 2020
  • TABLE 96. GLOBAL ANTICONVULSANTS MARKET: SHARE, BY COMPANY, 2020
  • TABLE 97. GLOBAL ANTICONVULSANTS MARKET: MERGER & ACQUISITION
  • TABLE 98. GLOBAL ANTICONVULSANTS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 99. GLOBAL ANTICONVULSANTS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 100. GLOBAL ANTICONVULSANTS MARKET: INVESTMENT & FUNDING
  • TABLE 101. GLOBAL ANTICONVULSANTS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 102. GLOBAL ANTICONVULSANTS MARKET: LICENSE & PRICING
  • TABLE 103. GLOBAL ANTICONVULSANTS MARKET: CONTACT DETAILS